Edwards Lifesciences: A Strategic Hold Amid Expansion and Anticipated Clinical Trials
Edwards Lifesciences Analyst Ratings
Truist Raises Price Target on Edwards Lifesciences to $110 From $105, Maintains Buy Rating
Maintaining Hold on Edwards Lifesciences Amid Strategic Expansion and Product Development
Jefferies Adjusts Price Target on Edwards Lifesciences to $105 From $102
Maintaining Hold on Edwards Lifesciences Amid TAVR Market Caution and Forecasted Sales Dip
Edwards Lifesciences Analyst Ratings
Citigroup Adjusts Price Target on Edwards Lifesciences to $106 From $105
Edwards Lifesciences Analyst Ratings
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating
Wolfe Research Adjusts Price Target on Edwards Lifesciences to $70 From $75
Edwards Lifesciences Analyst Ratings
Buy Rating Affirmed for Edwards Lifesciences on Growth and Market Positioning Prospects
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Edwards Lifesciences Analyst Ratings
Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98
Robust Growth and R&D Focus Solidify Buy Rating for Edwards Lifesciences
Edwards Lifesciences Analyst Ratings
Edwards Lifesciences: A Buy Rating With Strong Growth Prospects and Positive Market Dynamics
Edwards Lifesciences Analyst Ratings